Intellectual Property - Patents

Authorized patents

1. A dual copy human p53 gene recombinant adenovirus and its preparation method

          Patent number: ZL201610224992.5

2. A genetically engineered cell (CAR-NK) for treating tumors

      Patent number: ZL201910527599.7

Authorize the use of patents

1. Recombinant of virus vector and human tumor suppressor gene and its application

          Patent number: ZL02115228.4

2. Subclonial cell line of human embryonic kidney 293 cells

      Patent number: ZL03126889.7

3. Application of recombinant adenovirus vector and P53 gene

      Patent number: ZL03125129.3

4. Method for producing recombinant adenovirus from serum-free suspension cells and its  

pharmaceutical formulation production method

          Patent number: 2013106551569

5. New application of recombinant adenovirus P53 products in tumor treatment

      Patent number: ZL2005100002779.1

6. Activated Bax gene using adenovirus as a vector for the treatment of malignant tumors

      Patent number: ZL201110119618.6

Patent applications under review

1. A genetically engineered natural killer (NK) cell product and its application

          Patent number: 201810392435.3

2. Genetic engineering natural killer cell products for treating tumors

      Patent number: CN2018/103655

3. Method for producing recombinant adenovirus

      Patent number: 201810686129.0

4. Biological products for prevention of novel coronavirus

      Patent number: 202010107992.3

5. Mass production of recombinant adenovirus for novel coronavirus gene vaccine

      Patent number: 202010227660.9

6. Production method of recombinant adenovirus gene vaccine for prevention of COVID-19

      Patent number: 202010306624.1

7. Variable p53 gene and recombinant adenovirus for cancer treatment

      Patent number: 202010135916.3

8. Preparation method of recombinant adenovirus with multi allele p53 coding sequence

      Patent number: 202010386150.6